Case Report

Fibrous solitary tumor, a rare and ubiquitous neoplasy

Alejandro Ros*, Javier Cortés, Tatiana Belda, Alejandro Magán, Francisco J. Illán-Gambín, Elisa Aracil, and Carlos Serra

Department of Surgery, Radiology and Pathology, Verge dels Lliris Hospital, Polígono Carabanchel, s/n
CP: 03804, Alcoy, Spain

*Correspondence address. Tel: 0034 675070195; E-mail: alejandro.ros12@gmail.com

Abstract

Fibrous solitary tumors (FST) are mesenchymal tumors that can appear in different body regions. It is estimated that around 30% are found in the thoracic region, while rarely in meninges, abdomen, pelvis, extremities and bones. A correct diagnosis is important because 15–20% of cases develop a malignant behavior. Treatment of choice is surgical and posterior follow-up is essential. We present two atypical extrapleural FST cases, diagnosed in our center. Both were treated with surgery and in one case arterial embolization to reduce the bleeding risk was previously done.

INTRODUCTION

Fibrous solitary tumors (FST) are considered soft tissue mesenchymal tumors with a fibroblastic or myofibroblastic origin [1]. They were initially described as pleural tumors; however, there is literature describing them in many body regions. The most common location is in the pleura (between 30–80%) and less frequently in meninges and abdomen [2]. FST has an incidence of 2.8/100,000 population, with similar rates between men and women, and it is more frequent during the 50–60th decade. FST are usually asymptomatic with a slow growing behavior and in many cases, diagnosis is found incidentally in the image scans. In the abdomen, they can produce obstructive symptoms, mass effect or pain if size is big enough. Histologically, they use to have a prominent blood supply with a hemangiopericitic growth pattern. Immunohistochemistry (IHQ) shows CD34 and vimentin positivity. A correct diagnosis is very important as they are currently considered benign tumors, and surgery is the treatment of choice. Closer follow-up is strictly recommended if size is bigger than 10 cm or malignant histological component exists.

CASE REPORTS

This article presents two clinical cases of FST treated in our clinic. Both are extrapleural and with atypical location. The first was located in the prevesical space and the other in the superficial muscular aponeurosis. A review of the scientific literature is also done.

Case 1

A 43-year-old male patient was referred to hospital with mic turition disorders and hypogastric abdominal pain during the previous few months. A computerized tomography (CT) was carried out showing a pre-vesical mass 6 × 5 cm in size with well-defined borders and hypercaptant during the arterial phase (Fig. 1). As an FST was suggested, a fine-needle aspiration (FNA) biopsy was done, but diagnosis was not confirmed.

Radical surgery was decided after discussion in the tumors multidisciplinary committee, and previous vascular embolization was proposed to reduce the potential risk of bleeding (Fig. 2).
Laparoscopic approach is always an option but, in this case, to remove the tumor, we planned a Pfannenstiel incision. The decision was made due to the localization of the tumor.

During the surgery, the mass was identified at pre-vesical region (extra peritoneum) firmly attached to the pubis, in vicinity with the bladder, displacing it but without infiltration, so bladder resection was not needed (Fig. 3).

The pathologist report identifies a well-defined lesion 6 cm in diameter. Microscopically, fusocellular proliferation can be seen with hemangiopericytoid growth pattern, swirling and with abundant ‘deer antler’ shaped vessels. Absent necrosis is observed, and there are three non-atypical mitosis figures/40 high-power fields (HPF). It shows positivity for CD34, CD99, BCL2 and betacatenin (cytoplasmic) and negativity for CKAE1/AE3, desmin smooth muscle actin and S100. With these findings, benign TFS was diagnosed (Fig. 4).

Free surgical margins were obtained as normal adipose tissue surrounding the tumor was shown.

After 2 years of follow-up, the patient had a favorable outcome without tumoral recurrence.

Case 2

A 21-year-old male patient came to the consult with a supraumbilical slow growing lump. The mass was well defined, tender, simulating a supraumbilical incarcerated hernia. It was scarcely painful at examination. No tenderness and no enlargement with Valsalva maneuver were present and digestive symptoms were absent. With the initial diagnosis of an incarcerated epigastric hernia versus abdominal wall tumor, a preferent open surgery was decided due to the low benefit of laparoscopy in this case.

During the procedure, a hard, well-defined nodular lesion of approximately 4 cm in diameter was found. Histological analysis (AP) described a benign mesenchymal tumor, suggesting a TFS with optimal surgical margins.

Microscopically monomorphic cell proliferation between lax fibrous stroma with abundant vascularization of small caliber, not encapsulated and with infiltrative edges was seen. Intertwined beams with fusiform and star cells, oval nuclei, fine chromatin and elongated eosinophilic cytoplasm were also present. Some collagen fibers between cells and isolated non-atypical mitosis figures (0–1/10 HPF) were identified. Absence of necrosis. Immunohistochemically, positivity for CD34, CD99, bcl2 (cytoplasm) and smooth muscle actin were shown. Betacatenin, desmines and S100 were negative. Ki67 is 10–12% (Fig. 5).

Due to the results of FST, the case was discussed in the multidisciplinary tumors committee and follow-up as a low-risk tumor was made. After 1 year, the patient is asymptomatic and no recurrence has occurred.

**DISCUSSION**

TFS are rare mesenchymal neoplasms with a fibroblastic differentiation. Historically, they were described with different names (mesothelioma, pleural fibroma, submesothelial fibroma, subserosal fibroma and localized fibrous tumor). Hemangiopericytoma has been considered a different entity. However, the arrival of the IHQ diagnosis has led pathologists to consider it as the same entity, although the term of TFS is preferred [1].

Epidemiologically, about 2% of all soft tissue tumors are considered to be TFS [3]. The incidence is similar for men and
Fibrous solitary tumor, a rare and ubiquitous neoplasy

women. Though they can debut at any age, they usually appear between the fifth and sixth decade of life. They were first described by Klemperer and Rabin in 1931 at the thoracic region [4]. However, this tumor has been also registered in other body regions. TFS is generated in serous membranes and soft tissues. Approximately, 30% of cases are present in the thoracic cavity (including pleura, lungs and mediastinum). The peritoneal cavity, retroperitoneal soft tissues or pelvis represent the 30% of cases [5]. Approximately, 20% correspond to head and neck (including meninges). Less frequent locations are soft tissues of the trunk and extremities (10%) and bones.

The most frequent abdominal symptoms are palpable mass, weight loss and pain. Urinary or gastrointestinal symptoms have also been described due to compression. In the beginning, they are usually asymptomatic and sometimes when they are diagnosed, they have already reached a large size.

It is generally suspected after imaging tests. However, the final diagnosis requires histological confirmation.

The imaging tests required for diagnosis are CT scan or magnetic resonance imaging (MRI). Both show similar radiological characteristics to other soft tissue tumors, and there are no specific pathognomonic findings for TFS.

Its histological diagnosis is based on typically morphologic findings in conjunction with a characteristic immunophenotype. Complete resection of the tumor is necessary for proper study, and FNA is often not useful for diagnosis.

The purely histological differential diagnosis includes the deep fibromatosis (desmoid tumor), low-grade fibromyxoid sarcoma and myofibroblastic tumors. Desmoid tumors share many morphological features with TFS, but not its mutation of the APC gene that leads to overexpression of nuclear beta-catenin. Low-grade fibromyxoid sarcoma is another entity that should be ruled out when myxoid areas are observed, but in these tumors, the absence of MUC4 expression is characteristic. On the other hand, myofibroblastic tumors are usually positive for actin and/or desmines [6].

We consider essential that both the preoperative diagnosis and the postoperative evolution of the patient is to be made in a multidisciplinary way to achieve a correct scheduled treatment.

Size of TFS is quite variable. They are usually well defined, with a fibrous or serous pseudocapsule. Sometimes, they show multiple nodules and in general, excision of these tumors is easy.

Microscopically, they present fusiform cells, with elongated nucleus, dispersed chromatin and absent nucleolus, surrounded by scarce cytoplasm. The cells are surrounded by collagenous stroma. They frequently show a prominent vascularization, with hemangiopericytic growth pattern.

Immunohistochemistry has become the most useful tool to differentiate TFS from other tumors such as mesotheliomas or sarcomas [7]. Conventional markers usually include the expression of CD34, Bcl2, CD99, vimentin (in the absence of actin), desmin, S100 protein or epithelial markers.

Surgery in these tumors should be planned with the aim of achieving complete surgical resection with optimal margins as TFS can have a malignant behavior, and to avoid local recurrence.

The clinical behavior of these tumors is unpredictable. Most publications describe benign behavior, but between 15 and 20% of tumors produce metastases [8]. These patients have a worse
Figure 4: (A) hematoxylin–eosin, 4×. Slightly storiform diffuse proliferation. (B) HE, 20×. Fusiform cells with oval nuclei and extracellular collagen deposit. (C) CD34. (D) Ki67.

Figure 5: A. HE, 4x. Cells with diffuse growth. B. HE, 20x. Fusocellular neoplasia with clear eosinophilic cytoplasm and homogeneous elongated nuclei.

prognosis with a 75% mortality at 5 years. Generally, meningeal TFS tumors have a more aggressive behavior.

Tumor recurrence is usually due to peritoneal, pleural or meningeal tumor seeding due to systemic or hematic extension, or incomplete resection. They usually metastasize to lung, liver, brain and bone.

Malignant criteria are considered for large tumors (110 cm), with hypercellularity, high mitotic activity (>4 mitosis per 10CGA), pleomorphism, presence of hemorrhage or necrosis, infiltrative borders or loss of CD34 [9].

The recommended treatment is tumor exeresis. Its management should be discussed in a multidisciplinary committee with
are usually asymptomatic tumors. Diagnosis is led by imaging and established follow-up has been established. It is important to suspect this type of tumors when well-defined and hypervascularized lesions are found. They should always be removed and followed closely according to their malignant potential.

Table 1. Demicco’s malignancy risk classification

| N.°   | Points |
|-------|--------|
| Mitoses (per 10 HPF) |        |
| 0     | 0      |
| 1-3   | 1      |
| ≥4    | 2      |
| Age   |        |
| <55   | 0      |
| ≥55   | 1      |
| Size  |        |
| 0–4.9 cm | 0   |
| 5–9.9 cm | 1   |
| 10–14.9 cm | 2  |
| ≥15 cm | 3      |
| Necrosis |       |
| <10%   | 0      |
| ≥10%   | 1      |
| Risk sum stratification | Points |
| Low    | 0–3    |
| Intermediate | 4–5  |
| High   | 6–7    |

In conclusion, TFS are mesenchymal neoplasms more frequently in the pleural region, but can occur at any location. They are usually asymptomatic tumors. Diagnosis is led by imaging tests (CT scan and MRI) and surgical excision. Fine needle aspiration does not usually help the diagnosis. Surgical removal is the treatment of choice due to its malignant potential and is essential for proper diagnosis. Prior embolization can be considered in large and hypervascular tumors. The clinicopathological characteristics will allow us to classify its malignant potential and establish the follow-up scheme. It is important to suspect this type of tumors when well-defined and hypervascularized lesions are found. They should always be removed and followed closely according to their malignant potential.

REFERENCES

1. Fletcher CD, Bridge JA, Lee JC. Extrapleural solitary fibrous tumor. In: Fletcher CD, Bridge JA, Hogendoorn PC, Mertens F (eds). WHO Classification of Tumours of Soft Tissue and Bone. Lyon: IARC Press, 2013, 80
2. Davanzo B, Emerson RE, Lisy M, Koniaris LG, Kays JK. Solitary fibrous tumor. Transl Gastroenterol Hepatol 2018;3:94.
3. Gold JS, Antonescu CR, Hajdu C, Ferrone CR, Hussain M, Lewis JJ et al. Clinicopathologic correlates of solitary fibrous tumors. Cancer 2002;94:1057–68.
4. Klemperer P, Rabin CB. Primary neoplasms of the pleura. A report of five cases. Am J Ind Med. 1992;22:1–31.
5. Markku Meittinen. Chapter 12: Solitary fibrous tumor, hemangiopericytoma, and related tumors. In: Markku Meit­tinen (ed). Modern Soft Tissue Pathology: Tumours and Non-Neoplastic Conditions. New York: Cambridge University Press, 2010;335.
6. Rosai J. Respiratory tract. In: Rosai J (ed). Rosai and Ackerman Surgical Pathology, 10th edn. Edinburgh: Elsevier, 2013, 346–7.
7. De Perrot M, Fischer S, Bründler MA, Sekine Y, Keshavjee S. Solitary fibrous tumors of the pleura. Ann Thorac Surg 2002;74:285–93.
8. Gronchi A, Miceli R, Allard MA, Callegaro D, Le Péchéoux C, Fiore M et al. Personalizing the approach to retroperitoneal soft tissue sarcoma: histogenetic patterns of failure and postrelapse outcome after primary extended resection. Ann Surg Oncol 2015;22:1447–54.
9. DeVito N, Henderson E, Han G, Reed D, Bui MM, Lavey R et al. Clinical characteristics and outcomes for solitary fibrous tumor (SFT): a single Center experience. PloS One 2015;10:e0140362.
10. Penel N, Amela EY, Decanter G, Robin Y-M, Marec-Berard P. Solitary fibrous tumors and so-called hemangiopericytoma. Sarcoma 2012;2012:690251.
11. Demicco EG, Wagner MJ, Maki RG, Gupta V, Iofin I, Lazar AJ et al. Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model. Mod Pathol 2017;30:1433–42.